Survival Outcomes
high-grade, CFS
SECONDARY, RECURRENCE
Median (IQR) follow-up times for survival end points were 49 (27-79) months for patients receiving BCG and 23 (12-33) months for patients receiving gemcitabine and docetaxel. In the BCG group, 69 patients experienced recurrence, 60 experienced high-grade recurrence, 24 experienced progression, 37 died, and 10 died of cancer-related causes. In the gemcitabine and docetaxel group, 32 patients experienced recurrence, 28 experienced high-grade recurrence, 3 experienced progression, 21 died, and 0 died of cancer-related causes.For the primary outcome of high-grade RFS, 6-month estimates were 76% (95% CI, 69%-82%) in the BCG group and 92% (95% CI, 86%-95%) in the gemcitabine and docetaxel group, and 1-year estimates were 71% (95% CI, 64%-78%) in the BCG group and 85% (95% CI, 78%-91%) in the gemcitabine and docetaxel group. Two-year estimates were 69% (95% CI, 62%-76%) in the BCG group and 81% (95% CI, 72%-87%) in the gemcitabine and docetaxel group.For secondary survival outcomes, the 2-year estimates in the BCG group were 62% (95% CI, 54%-69%) for RFS, 94% (95% CI, 88%-97%) for CFS, 92% (95% CI, 86%-95%) for PFS, 98% (95% CI, 94%-99%) for CSS, and 93% (95% CI, 88%-96%) for OS. The 2-year estimates in the gemcitabine and docetaxel group were 78% (95% CI, 69%-85%) for RFS, 98% (95% CI, 93%-100%) for CFS, 97% (95% CI, 92%-99%) for PFS, 100% (95% CI, 100%-100%) for CSS, and 89% (95% CI, 81%-94%) for OS (